EUCTR2009-013671-21-BE进行中（未招募）不适用
A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of Age
ovartis Vaccines and Diagnostics S.r.l.0 个研究点目标入组 600 人开始时间: 2009年7月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females 18 years of age and above on the day of enrollment;
- •2. Individuals in good health as determined by the outcome of medical history, physical assessment and clinical judgment of the investigator
- •3. Individuals are able to comply with all study procedures and are available for all clinic visits scheduled in the study
- •4. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Individuals who are not able to comprehend and to follow all required study procedures for the whole period of the study;
- •2. Individuals with history or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study;
- •3. Individuals with any serious chronic or progressive disease according to judgment of the investigator (including, but not limited to neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease);
- •4. History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to influenza viral proteins, to any excipients.
- •5. Individuals who have had adjuvanted influenza vaccine or documented confirmed or suspected influenza disease within 3 months prior to Day 1;
- •6. Receipt of another investigational agent within 4 weeks prior to enrollment, or before completion of the safety follow-up period in this or in another study; unwilling to refuse participation in another clinical study through the end of this study;
- •7. Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccines; the only exception being plain seasonal influenza vaccines which are allowed until 1 week prior to and after 1 week study vaccinations.
- •8. Individuals who have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks;
- •9. Individuals with axillary temperature = 38 degrees Celsius (= 100.4° F) or oral temperature = 38.5 (=101.3° F) within 3 days of intended study vaccination;
- •10. Known or suspected impairment/alteration of immune function, for example resulting from:
- •a. receipt of immunosuppressive therapy such as systemic corticosteroids known to be associated with the suppression of hypothalamic-pituitary-adrenal (HPA) axis (15 mg/day of prednisone or its equivalent) or chronic use of inhaled high-potency corticosteroids (e.g. budesonide 800µg/day or fluticasone 750µg/day) within 60 days
- •prior to Visit 1,
- •b. cancer chemotherapy,
- •c. receipt of immunostimulants within 60 days prior to Visit 1,
- •d. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Visit 1 or planned during the full length of the study,
- •e. known HIV infection or HIV-related disease;
- •11. History of progressive or severe neurological disorders (including Guillain-Barré syndrome and convulsions, but excluding febrile convulsions);
- •12. History of or clinically suspected developmental delay
- •13. Bleeding diathesis;
- •14. Surgery planned during the study period that in the Investigator’s opinion would interfere with the study visits schedule;
- •15. If female, of childbearing potential, and has not used any of the acceptable contraceptive methods” for at least 2 months prior to study entry
- •a. Female of childbearing potential is defined as a post onset of menarche or pre-menopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 year earlier, or (3) total hysterectomy.
- •b. Acceptable birth control methods are defined as one or more of the following:
- •i. Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring)
- •ii. Barrier (condom with spermicide or diaphragm with spermicide) ea
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of AgeEUCTR2009-013639-39-BEovartis Vaccines and Diagnostics S.r.l.600
进行中（未招募）
不适用
A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of AgePandemic influenzaEUCTR2009-013671-21-NLovartis Vaccines and Diagnostics S.r.l.600
进行中（未招募）
1 期
A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of AgePandemic influenzaEUCTR2009-013671-21-DEovartis Vaccines and Diagnostics S.r.l.600
进行中（未招募）
1 期
A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of AgePandemic influenzaEUCTR2009-013639-39-DEovartis Vaccines and Diagnostics S.r.l.600
进行中（未招募）
不适用
A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects from 6 Months to 17 Years of AgePandemic influenzaEUCTR2009-013640-37-DEovartis Vaccines and Diagnostics S.r.l.720